

Serial No.: 10/600,152

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for the treatment of a human patient susceptible to or diagnosed with a disorder characterized by overexpression of ErbB2 receptor, comprising administering an effective amount of an anti-ErbB2 antibody to the human patient, the method comprising:
administering to the patient an initial dose of at least approximately 5 mg/kg of the anti-ErbB2 antibody; and
administering to the patient a plurality of subsequent doses of the antibody in an amount that is approximately the same or less than the initial dose; and
further comprising administering an effective amount of a chemotherapeutic agent to the patient.
2. (original) The method of claim 1, wherein the initial dose is at least approximately 6 mg/kg.
3. (original) The method of claim 2, wherein the initial dose is at least approximately 8 mg/kg.
4. (original) The method of claim 3, wherein the initial dose is at least approximately 12 mg/kg.
5. (original) The method of claim 1, wherein the subsequent doses are separated from each other in time by at least one week.
6. (original) The method of claim 1, wherein the subsequent doses are separated in time from each other by at least two weeks.
7. (original) The method of claim 1, wherein the subsequent doses are separated in time from each other by at least three weeks.
8. (original) The method of claim 1, wherein the initial dose is administered by intravenous injection, and wherein at least one subsequent dose is

Serial No.: 10/600,152

administered by subcutaneous injection.

9. (original) The method of claim 1, wherein the initial dose is administered by intravenous injection, wherein at least two subsequent doses are administered, and wherein each subsequent dose is administered by a method selected from the group consisting essentially of intravenous injection and subcutaneous injection.

10. (original) The method of claim 1, wherein the initial dose and at least one subsequent dose are administered by subcutaneous injection.

11. (original) The method of claim 1, wherein the initial dose is selected from the group consisting essentially of approximately 6 mg/kg, 8 mg/kg, or 12 mg/kg, wherein the plurality of subsequent doses are at least approximately 2 mg/kg, and wherein the subsequent doses are separated in time from each other by at least one week.

12. (original) The method of claim 11, wherein the plurality of subsequent doses are separated in time from each other by at least two weeks.

13. (original) The method of claim 12, wherein the plurality of subsequent doses are separated in time from each other by at least three weeks.

14. (original) The method of claim 13, wherein the initial dose is approximately 8 mg/kg, and wherein at least one subsequent dose is approximately 6 mg/kg.

15. (original) The method of claim 13, wherein the initial dose is approximately 12 mg/kg, and wherein at least one subsequent dose is approximately 6 mg/kg.

16. (original) The method of claim 11, wherein the initial dose is approximately 8 mg/kg, and wherein at least one subsequent dose is approximately 8 mg/kg.

17. (original) The method of claim 11, wherein the initial dose is approximately 8 mg/kg, wherein at least one subsequent dose is 8 mg/kg, and wherein administration of the initial dose and subsequent doses are separated

Serial No.: 10/600,152

in time by at least 2 weeks.

18. (original) The method of claim 17, wherein the initial dose and subsequent doses are separated in time by at least 3 weeks.

19. (original) The method of claim 1, wherein the initial dose is a plurality of doses, wherein each of the plurality of initial doses is at least approximately 1 mg/kg and is administered on at least 2 consecutive days, wherein the at least one subsequent dose is at least approximately 2 mg/kg, and wherein administration of the last initial dose and the first subsequent and additional subsequent doses are separated in time by at least one week.

20. (original) The method of claim 19, wherein the initial dose is a plurality of doses, wherein each of the plurality of initial doses is at least approximately 1 mg/kg and is administered on at least 3 consecutive days, wherein the at least one subsequent dose is at least approximately 6 mg/kg, and wherein administration of the last initial dose and the first subsequent and additional subsequent doses are separated in time by at least 3 weeks.

21. (original) The method of claim 1, wherein the initial dose is a plurality of doses, wherein each of the plurality of initial doses is at least approximately 1 mg/kg and is administered at least twice per week for 3 weeks as a first dosage cycle, wherein the dosage cycle is repeated, and wherein the doses of each cycle are separated in time by at least 1 day, and wherein the dosage cycles are separated in time by at least 1 week.

22. (original) The method of claim 1, wherein said disorder is a benign or malignant tumor.

23. (original) The method of claim 1, wherein said disorder is a cancer.

24. (original) The method of claim 23, wherein said cancer is selected from the group consisting of breast cancer, leukemia, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various

Serial No.: 10/600,152

types of head and neck cancer.

25. (original) The method of claim 24, wherein said cancer is breast cancer.

26. (original) The method of claim 25, wherein said cancer is metastatic breast carcinoma.

27. (original) The method of claim 1 wherein said antibody binds to the extracellular domain of the ErbB2 receptor.

28. (original) The method of claim 27, wherein said antibody binds to epitope 4D5 within the ErbB2 extracellular domain sequence.

29. (original) The method of claim 28, wherein said antibody is a humanized 4D5 anti-ErbB2 antibody.

30. (cancelled)

31. (currently amended) The method of claim 1 ~~30~~, wherein the chemotherapeutic agent is a taxoid.

32. (original) The method of claim 31, wherein said taxoid is paclitaxel or docetaxel.

33. (currently amended) The method of claim 1 ~~30~~, wherein the effective amount of the anti-ErbB2 antibody and the effective amount of the chemotherapeutic agent as a combination is lower than the sum of the effective amounts of said anti-ErbB2 antibody and said chemotherapeutic agent, when administered individually, as single agents.

34. (currently amended) The method of claim 1 ~~30~~, wherein the chemotherapeutic agent is an anthracycline derivative.

35. (original) The method of claim 34, wherein the anthracycline derivative is doxorubicin or epirubicin.

36. (original) The method of claim 34, wherein the method further comprises

Serial No.: 10/600,152

administration of a cardioprotectant.

37. (original) The method of claim 1, wherein efficacy is measured by determining the time to disease progression or the response rate.

38-85. (cancelled)

86. (currently amended) A method for the treatment of cancer in a human patient comprising administering to the patient a first dose of an anti-ErbB2 antibody followed by at least one subsequent dose of the antibody, wherein the first dose and subsequent dose are separated from each other in time by at least about two weeks, and further comprising administering an effective amount of a chemotherapeutic agent to the patient.

87. (original) The method of claim 86, wherein the first dose and subsequent dose are separated from each other in time by at least about three weeks.

88. (original) The method of claim 86, wherein the first dose and subsequent dose are each from about 2mg/kg to about 16mg/kg.

89. (original) The method of claim 88, wherein the first dose and subsequent dose are each from about 4mg/kg to about 12mg/kg.

90. (original) The method of claim 89, wherein the first dose and subsequent dose are each from about 6mg/kg to about 12mg/kg.

91. (original) The method of claim 86, wherein two or more subsequent doses of the antibody are administered to the patient.

92. (original) The method of claim 91, wherein from about two to about ten subsequent doses of the antibody are administered to the patient.

93. (original) The method of claim 91, wherein the two or more subsequent doses are separated from each other in time by at least about two weeks.

94. (original) The method of claim 93, wherein the two or more subsequent doses are separated from each other in time by at least about three weeks.

Serial No.: 10/600,152

95. (original) The method of claim 91, wherein the two or more subsequent doses are each from about 2mg/kg to about 16mg/kg.

96. (original) The method of claim 91, wherein the two or more subsequent doses are each from about 4mg/kg to about 12mg/kg.

97. (original) The method of claim 91, wherein the two or more subsequent doses are each from about 6mg/kg to about 12mg/kg.

98. (cancelled)

99. (currently amended) The method of claim ~~86~~ ~~98~~, wherein the chemotherapeutic agent is a taxoid.

100. (cancelled)

101. (currently amended) A method for the treatment of cancer in a human patient, comprising administering an effective amount of an anti-ErbB2 antibody to the human patient, the method comprising:
administering to the patient an initial dose of at least approximately 5 mg/kg of the ~~anti-ErbB~~ antibody; and administering to the patient a plurality of subsequent doses of the antibody in an amount that is approximately the same or less than the initial dose, and further comprising administering an effective amount of a chemotherapeutic agent to the patient.

102-105. (cancelled)